Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 85,300 shares, a growth of 5.7% from the November 30th total of 80,700 shares. Based on an average daily trading volume, of 70,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 7.8% of the company’s shares are short sold.

Cadrenal Therapeutics Stock Performance

NASDAQ:CVKD opened at $15.50 on Friday. The stock’s 50-day moving average price is $14.74. Cadrenal Therapeutics has a 52-week low of $5.40 and a 52-week high of $32.55. The company has a market capitalization of $27.64 million, a P/E ratio of -2.32 and a beta of 1.22.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their target price on Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, November 11th.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.